Nanoscope Therapeutics has moved MOGENRY into formal FDA review for severe vision loss caused by retinitis pigmentosa. The therapy’s optogenetic strategy is unusual because it attempts to restore light sensitivity in surviving retinal cells regardless of the patient’s underlying mutation, potentially expanding gene therapy beyond one-gene-one-drug models.
FDA accepts Nanoscope’s MOGENRY BLA for severe retinitis pigmentosa, moving a mutation-independent optogenetic therapy into formal review.
The FDA has accepted Nanoscope Therapeutics’ BLA for MOGENRY, an optogenetic therapy designed to restore useful vision in severe retinitis pigmentosa regardless of the underlying mutation.
Two-year RESTORE results show sustained disability, pain and quality-of-life improvements with Mainstay Medical’s ReActiv8 restorative neurostimulation system for chronic low back pain.
eGenesis says five patients have received EGEN-2784 pig kidneys under Expanded Access, with three maintaining kidney function beyond eight months and two later receiving human donor kidneys.